Announcements Trials
Browse Landscape Eligibility

Clinical Trials

2 trials
RecentStart dateEnrollment
Genes × Clear all

Phase

Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Lymphoma, AIDS-Related 1Lymphoma 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Cisplatin 3176Cyclophosphamide 3172Carboplatin 2955Radiotherapy 2771Paclitaxel 2705Gemcitabine 2549pembrolizumab 2368Bevacizumab 2192Docetaxel 2190Fluorouracil 1837Capecitabine 1815Oxaliplatin 1723Dexamethasone 1592Nivolumab 1575Doxorubicin 1500Rituximab 1480Magnetic Resonance Spectroscopy 1365Etoposide 1341Irinotecan 1240Leucovorin 1215Drug Therapy 1189Cytarabine 1126Pemetrexed 1067fludarabine 1035Specimen Handling 985Vincristine 964Prednisone 940Cetuximab 938Trastuzumab 936Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT00858793 2022-09-08

High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Terminated
5 enrolled
Lymphoid

Acquired Immunodeficiency Syndrome, Lymphoma, HIV Infections, Lymphoma, AIDS-Related

NCT03152448 2022-06-13

P-PROVE

Myriad Genetic Laboratories, Inc.

Terminated
1,511 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡